Eli Lilly and Company has announced an agreement with AbbVie Inc. to acquire the global rights to clazakizumab, an investigational IL-17A inhibitor. The transaction, valued at up to $1.5 billion, is expected to enhance Lilly's immunology pipeline.

Clazakizumab is currently being evaluated in Phase 3 studies for the treatment of psoriatic arthritis and has also been studied in other inflammatory conditions. Under the terms of the agreement, Lilly will make an upfront payment of $300 million to AbbVie, with potential milestone payments totaling up to $1.2 billion contingent on the drug's development and commercial success.

The acquisition is subject to customary closing conditions and regulatory approvals. This deal signifies Lilly's continued investment in expanding its therapeutic offerings in the immunology space.

Key Takeaways

• Eli Lilly is acquiring global rights to AbbVie's investigational drug clazakizumab.
• The deal has a potential total value of up to $1.5 billion, including an upfront payment and milestone payments.
• Clazakizumab is an IL-17A inhibitor being studied for psoriatic arthritis and other inflammatory diseases.
• The acquisition aims to strengthen Lilly's immunology pipeline.

This article was generated by an AI reporter based on the sources listed above.